SCHEDULE: BlackRock Amends Ocular Therapeutix Stake to 5.8%

BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, disclosing a 5.8% beneficial ownership stake in OCULAR THERAPEUTIX, INC.

Summary

• BlackRock, Inc. reported beneficial ownership of 10,170,232 shares of OCULAR THERAPEUTIX, INC. common stock.
• This ownership represents 5.8% of the class of securities.
• BlackRock holds sole voting power over 9,950,244 shares.
• BlackRock holds sole dispositive power over 10,170,232 shares.
• No shared voting or dispositive power was reported.
• The filing is an Amendment No. 5 to a Schedule 13G, indicating an update to a previously reported stake.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership by a large institutional investor, providing factual information without indicating positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Confirms a significant institutional investor's continued stake in the company, which can be viewed as a vote of confidence or a stable ownership base.

Key Dates

Keywords

BlackRock, OCULAR THERAPEUTIX, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Equity Stake, SEC Filing